Financials
| Preliminary results for the year ended 31 Dec 2024 | May. 06, 2025 |
| Trading Update | Jan. 13, 2025 |
| Trading Update | Nov. 07, 2024 |
| Half yearly Report | Sep. 23, 2024 |
| Preliminary results for the year ended 31 Dec 2023 | May. 07, 2024 |
| Trading Update | Jan. 22, 2024 |
| Half Yearly Report | Sep. 29, 2023 |
Proxies
| Result of AGM | Jun. 27, 2024 |
| AGM Statement | Jun. 27, 2024 |
| Publication of Annual Report and Notice of AGM | Jun. 05, 2024 |
| Result of AGM | Jun. 30, 2023 |
| AGM Statement | Jun. 29, 2023 |
| Publication of Annual Report and Notice of AGM | Jun. 07, 2023 |
| Result of AGM | Jun. 29, 2022 |
Ownership Update
| Holding(s) in Company | May. 06, 2025 |
| Director/PDMR Shareholdings | Apr. 01, 2025 |
| Director/PDMR Shareholding | Mar. 05, 2025 |
| Director/PDMR Shareholding | Mar. 05, 2025 |
| Director/PDMR Shareholdings | Mar. 04, 2025 |
| Director/PDMR Shareholding | Feb. 06, 2025 |
| Director/PDMR Shareholdings | Jan. 28, 2025 |
Announcements
| Mevalone Approval in California - Powdery Mildew | May. 13, 2025 |
| Investor Presentation via Investor Meet Company | May. 09, 2025 |
| Thymol Supply Agreement For Bee Health | Apr. 10, 2025 |
| Appointment of Distribution Partner in Kenya | Mar. 24, 2025 |
| Appointment of Joint Broker | Mar. 10, 2025 |
| Investor Presentation via Investor Meet Company | Feb. 05, 2025 |
| Regulatory approval for Novellus+ in Mexico | Dec. 20, 2024 |